A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Inclusion Criteria: * Has histologically confirmed diagnosis of advanced/unresectable malignant pleural mesothelioma (MPM) * Have at least one measurable disease, which is systemic therapy naïve, radiologically assessed by the local site investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) using imaging scanned within 28 days prior to the first dose in this study * Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale * Has a life expectancy of at least 3 months * Demonstrate adequate organ function * Male participants are eligible to participate if they agree to remain abstinent or agree to use contraception unless confirmed to be azoospermic * A female participant is eligible to participate if she is not pregnant or breastfeeding, using contraceptives or is not a woman of child bearing potential (WOCBP) Exclusion Criteria: * A WOCBP who has a positive pregnancy test within 72 hours prior to treatment allocation * Has received prior therapy with an anti-programmed cell-death 1 (anti PD-1), anti programmed cell-death ligand 1 (anti-PD-L1), or anti programmed cell-death ligand 2 (anti PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor * Has previously received systemic anti-cancer therapy (including investigational agents) for MPM * Participants who received (neo) adjuvant previously may be eligible, only if the last dose of chemotherapy was completed at le…